CFAP43 variant in persistent respiratory symptoms after hematopoietic cell transplantation

Introduction

Impaired mucociliary clearance of epithelial cilia in the lungs, paranasal sinuses, and ears leads to recurrent and chronic infections of the airways1,2. Primary ciliary dyskinesia (PCD) is a heterogeneous disorder of motile cilia dysfunction typically caused by autosomal-recessive disease3. Approximately 50 genes have been linked to PCD. More than 70% of patients with PCD have pathogenic variants of these genes3.

CFAP43 encodes a member of the cilia- and flagella-associated protein families. Variants of CFAP43 have been reported to be responsible for normal pressure hydrocephalus (NPH) and male infertility with multiple morphological abnormalities of the flagella (MMAF)4,5. However, the relevance of CFAP43 variants in PCD is unclear.

Herein, we describe the case of a patient with a heterozygous CFAP43 variant who developed persistent respiratory symptoms after hematopoietic cell transplantation (HCT).

Case presentation

An 18-month-old Japanese girl with short stature ( − 2.7 SD) presented with a mass in her left oropharynx. Hepatosplenomegaly was also observed. She was born at term and experienced no respiratory symptoms during the neonatal period. Bronchial asthma was diagnosed during infancy and treated with inhaled corticosteroids and leukotriene antagonists. None of the family members had symptoms mimicking PCD or were diagnosed with PCD, bronchial asthma, or chronic respiratory infection. Blood examinations revealed autoimmune hemolytic anemia and thrombocytopenia. A genetic analysis of mononuclear cells in the peripheral blood revealed a KRAS c.37 G > T p.G13C mutation without any mutations in FAS, FAS-ligand, or caspase 10. No mutation was identified in the buccal mucosal cells, suggesting a somatic mutation. Based on these findings, the patient was diagnosed with RAS-associated autoimmune leukoproliferative disease (RALD).

The patient was treated with cyclosporine, mercaptopurine, and prednisolone; however, her symptoms (hepatosplenomegaly and an oropharyngeal mass) and cytopenia persisted. Recurrent otitis media and pneumonia are complications of an immunosuppressive state. The patient was refractory to immunosuppressive therapy; therefore, HCT was conducted. The conditioning regimen was a myeloablative conditioning regimen consisting of busulfan (16.96 mg/kg), fludarabine (120 mg/m2), and melphalan (180 mg/m2) at 56 months of age. Complete donor chimerism was achieved on Day 43. The tumor in the left oropharynx had disappeared. Furthermore, complete hematological normalization (including a thrombocyte count of >100 × 103/μL) after HCT was successfully achieved on Day 384.

Eleven months after HCT, the patient developed pneumonia, sinusitis, and otitis media from mild respiratory symptoms, which required hospitalization with intravenous antibiotics in addition to leukotriene receptor antagonists, antihistamines, mucoactive agents, and bronchodilator agents (Fig. 1). Sputum and otorrhea cultures revealed Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus, and Haemophilus influenzae. The administration of several antibiotics to which these pathogens were sensitive succeeded in improving the clinical data, including the WBC and C-reactive protein level. However, the patient’s clinical symptoms did not improve. There was no history or laboratory data suggestive of airway infection (e.g., viral [respiratory syncytial virus, human metapneumovirus, or influenza]), fungal infection, or nontuberculous mycobacteria. Tympanostomy tube insertion was performed in both ears. Immunosuppressive therapy was discontinued 20 months after HCT, although only hypoplasia of the nails associated with mild chronic graft-versus-host disease was recognized. The symptoms related to impaired mucociliary clearance persisted for 7 years, alternating between periods of improvement and exacerbations. Immunological studies revealed complete recovery from the immunocompromised state at 32 months after HCT: IgG, 1384 mg/dL; IgA, 163 mg/dL; IgM, 134 mg/dL; 26.3% CD19-positive lymphocytes; 47.8% CD3-positive lymphocytes; 20.8% CD4-positive lymphocytes; 19.9% CD8-positive lymphocytes; T-cell response to phytohemagglutinin, 37,400 cpm (normal range: 26,000–53,000); and concanavalin A 36,000 cpm (normal range: 20,300–65,700). Chest computed tomography revealed prominent bronchial wall thickening in the lower lobes of the right lung, suggesting impaired ciliary function (Fig. 2a). Light microscopy of a biopsy sample from the nasal mucosa revealed focal ciliated cells (Fig. 2b). Electron microscopy revealed the presence of 1 pair of central singlets and 9 pairs of peripheral doublets with a normal ciliary ultrastructure (data not shown), although the number of cilia was decreased. A targeted next-generation sequencing panel of 32 PCD-related genes (Supplemental Table 1) failed to identify any variants. Whole-exome sequencing of the patient’s peripheral blood mononuclear cells (stored before receiving HCT) and her parents was performed with written informed consent from the patient’s guardians. A heterozygous variant of CFAP43 (c.4506 G > A, p.Trp1502Ter, rs1327299547, minor allele population frequency = 0.000004) was identified in both the patient and her mother (Fig. 2c). We hypothesized that the heterozygous CFAP43 variant might impair ciliary function and cause persistent respiratory symptoms after HCT. Clarithromycin (100 mg/day) was administered for a period of 14 months. After the cessation of clarithromycin, her respiratory function was maintained. At 84 months after HCT, only mucoactive agents were necessary for chronic otitis media.

Fig. 1: Clinical course of the patient.
figure 1

At 11 months after HCT, the patient’s mild respiratory symptoms were exacerbated, and she developed pneumonia, sinusitis, and otitis media. Mucoactive agents, antihistamines, leukotriene receptor antagonists, bronchodilator agents, and clarithromycin were administered. Tympanostomy tubes were also inserted. At 12 years of age, only mucoactive agents were necessary for chronic otitis media.

Full size image
Fig. 2: Radiological, pathological, and genetic features of the patient.
figure 2

a Computed tomography scan of the chest 23 months after hematopoietic cell transplantation. The arrows highlight changes in bronchial wall thickening in the right lower lobe (red arrows). b Toluidine blue staining of the nasal mucosa. On light microscopy of nasal cilia, ciliated cells were only focally observed (black arrow). c Electropherograms showing heterozygous variants of CFAP43 (c.4506 G > A) in the patient and her mother.

Full size image

Discussion

CFAP43 is located on chromosome 10. It contains 38 exons encoding a predicted 1665-amino-acid protein that is specifically expressed in the human testis. The biallelic CFAP43 pathogenic variant causes male infertility with MMAF; however, these patients do not present with any PCD-associated symptoms, such as sinusitis, rhinitis or chronic bronchitis6. Morimoto et al. 4 described the same heterozygous CFAP43 variant identified in our patient, which induced NPH in a Japanese family member. Notably, these patients had recurrent respiratory infections and chronic sinusitis. CFAP43-deficient mice generated by Morimoto et al. presented a hydrocephalus phenotype with morphological abnormalities in motile cilia, mimicking normal-pressure hydrocephalus in humans4. Moreover, immunofluorescence staining of brain ventricular and tracheal tissue using targeted antibodies confirmed the abnormal ciliary protein composition in CFAP43-deficient mice. Transmission electron microscopy of respiratory tract cilia from patients (nasal mucosa) and CFAP43-deficient mice (tracheal tissue) confirmed the presence of abnormal ciliary ultrastructures. These findings suggest that CFAP43 affects not only the testis but also other tissues, including epithelial cells of the ventricles of the brain and trachea. However, no other hallmark features of PCD, such as neonatal respiratory distress and chronic ear infections, were identified in patients with a heterozygous CFAP43 variant. Although our patient experienced recurrent episodes of pneumonia and otitis media during immunosuppressive therapy, no neonatal respiratory distress was observed. These respiratory symptoms worsened after HCT and required long-term treatment. The same heterozygous CFAP43 variant was found upon sequence analysis of the patient’s mother, who had no respiratory symptoms. This observation suggests that incomplete penetrance of the CFAP43 variant or environmental modifiers can affect the development of PCD under the CFAP43 variant. HCT-associated bronchial damage may be associated with PCD mimicking symptoms under the CFAP43 variant.

Upper respiratory infections are a frequent complication in patients undergoing HCT. Immunosuppression is the main triggering factor, as the airway is the location most exposed to the environment and its microorganisms. The frequency of bacterial rhinosinusitis in patients receiving HCT is much greater (21–37%) than that in immunocompetent patients (5–15%)7. Biliary dysfunction and structural damage occur in patients undergoing HCT due to chemotherapy, irradiation, respiratory infections, and graft-versus-host disease. Ortiz et al.8 reported reductions in the number of cilia (77%) and goblet cells (50%) and a 50% change in ciliary ultrastructure after HCT. Our patient also presented a decreased number of cilia.

Utimisheva et al.9 reported that recovery from sinusitis occurred within 15 days in 5% and within 30 days in 92.5% of patients after HCT. The treatment period exceeded 100 days after HCT in only 2.5% of the patients. The longest treatment period was 240 days. In a previous report, ciliary dysfunction and structural damage after HCT usually improved spontaneously within 10 weeks1. Respiratory symptoms persisted for more than 36 months after the patient reached an immunocompetent state. Therefore, the heterozygous CFAP43 variant may have affected the severe phenotype observed in our patient.

One limitation of our case is that transmission electron microscopy during the recovery period did not reveal abnormal ciliary ultrastructures. We failed to obtain adequate biopsy material when the patient presented with the most severe symptoms. Morimoto et al.4 reported a mixture of normal and abnormal ciliary ultrastructures in the nasal mucosa of patients. There is a possibility of abnormal cilia in our patient. More patients are needed to clarify the abnormal ciliary ultrastructure caused by CFAP43.

Conclusion

Heterozygous CFAP43 nonsense variants may lead to persistent respiratory symptoms after HCT. The establishment of screening for patient management before HCT would help to avoid subsequent complications.

HGV Database

The relevant data from this Data Report are hosted at the Human Genome Variation Database at https://doi.org/10.6084/m9.figshare.hgv.3450.

Related Articles

Structure and function relationships of mucociliary clearance in human and rat airways

Mucociliary clearance is a vital defense mechanism of the human airways, protecting against harmful particles and infections. When this process fails, it contributes to respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. While advances in single-cell transcriptomics have revealed the complexity of airway composition, much of what we know about how airway structure impacts clearance relies on animal studies. This limits our ability to create accurate human-based models of airway diseases. Here we show that the airways in female rats and in humans exhibit species-specific differences in the distribution of ciliated and secretory cells as well as in ciliary beat, resulting in significantly higher clearance effectiveness in humans. We further reveal that standard lab-grown cultures exhibit lower clearance effectiveness compared to human airways, and we identify the underlying structural differences. By combining diverse experiments and physics-based modeling, we establish universal benchmarks to assess human airway function, interpret preclinical models, and better understand disease-specific impairments in mucociliary clearance.

The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT

In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were CAR-T. Compared to the previous year there was an increase in CAR-T (+52.5%), in allogeneic HCT (+7.8%) but none in autologous HCT (+0.4%). Main indications for allogeneic HCT were myeloid (11,748; 60.7%), lymphoid malignancies (4,850; 25.0%), and non-malignant disorders (2558; 13.2%). Use of allogeneic HCT increased for AML (+12.1%) and for NHL (+11.0%), particularly in T-NHL (+25.6%). Main indications for autologous HCT were lymphomas (7890; 32.2%), PCD (14,271; 58.2%), and solid tumors (1608; 6.6%) with recovering numbers for autoimmune diseases. In patients with allogeneic HCT, the use of sibling donors increased by +1.0%, haploidentical donors by +11.7%, and unrelated donors by +11.1%. Cord blood HCT decreased again by −5.4%. Pediatric HCT activity increased slightly (5455; +0.1%) with differences between allogeneic (4111; −0.5%) and autologous HCT (1344: +1.7%). Use of CAR-T increased to a cumulative total of 13,927 patients including patients treated for autoimmune diseases. Overall, numbers show a complete recovery from the pandemic dip with increased cellular therapy at the expense of autologous HCT. Allogeneic HCT activity focuses on myeloid malignancies.

Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates

Refractory disease and relapse are major challenges in acute myeloid leukemia (AML) therapy attributed to survival of leukemic stem cells (LSC). To target LSCs, antibody-drug conjugates (ADCs) provide an elegant solution, combining the specificity of antibodies with highly potent payloads. We aimed to investigate if FLT3-20D9h3-ADCs delivering either the DNA-alkylator duocarmycin (DUBA) or the microtubule-toxin monomethyl auristatin F (MMAF) can eradicate quiescent LSCs. We show here that DUBA more potently kills cell-cycle arrested AML cells compared to microtubule-targeting auristatins. Due to limited stability of 20D9h3-DUBA ADC in vivo, we analyzed both ADCs in advanced in vitro stem cell assays. 20D9h3-DUBA successfully eliminated leukemic progenitors in vitro in colony-forming unit and long-term culture initiating cell assays, both in patient cells and in patient-derived xenograft (PDX) cells. Further, it completely prevented engraftment of AML PDX leukemia-initiating cells in NSG mice. 20D9h3-MMAF had a similar effect in engraftment assays, but a less prominent effect in colony assays. Both ADCs did not affect healthy stem and progenitor cells at comparable doses providing the rationale for FLT3 as therapeutic LSC target. Collectively, we show that FLT3-directed ADCs with DUBA or MMAF have potent activity against AML LSCs and represent promising candidates for further clinical development.

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Responses

Your email address will not be published. Required fields are marked *